Holen Sie sich die Stockscreener-App
3.56
1.10%
0.06
Schlusskurs vom Vortag:
$3.62
Offen:
$3.67
24-Stunden-Volumen:
70,959
Relative Volume:
0.87
Marktkapitalisierung:
$45.74M
Einnahmen:
$134.00K
Nettoeinkommen (Verlust:
$-33.51M
KGV:
-1.1099
EPS:
-3.2074
Netto-Cashflow:
$-18.15M
1W Leistung:
-12.02%
1M Leistung:
-30.68%
6M Leistung:
-33.33%
1J Leistung:
-44.55%
1-Tages-Spanne:
$3.51
$3.84
1-Wochen-Bereich:
$3.60
$4.2172
52-Wochen-Spanne:
$3.60
$13.50
Clene Inc Stock (CLNN) Company Profile
Firmenname
Clene Inc
Sektor
Branche
Telefon
801-676-9695
Adresse
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.56 | 46.51M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
521.93 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.00 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.66 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.46 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-28 | Eingeleitet | Oppenheimer | Outperform |
Clene Inc Aktie (CLNN) Neueste Nachrichten
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com India
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - Stocktwits
Clene to Present at Upcoming September Investor Conferences - Investing News Network
Two investor conferences in New York will hear from Clene this month - Stock Titan
CLENE Q2 BASIC EPS USD -1.08 - Moomoo
Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail
Clene (CLNN) Outlook: Adds 4.30% to Close at $4.37 at the Close; Price Context: the Near-Term Reference Band Stretches From $4.15 to $4.59 under the Current SnapshotQuote Data - vinanet.vn
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat
Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com
CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView
Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network
HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo
Clene to Present at the Emerging Growth Conference - Investing News Network
Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
Clene earnings missed by $0.75, revenue topped estimates - Investing.com
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
Clene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Clene Inc. For: 14 August By Investing.com - Investing.com Canada
Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights - The Manila Times
Clene Inc. (NASDAQ: CLNN) widens Q2 loss while preparing accelerated ALS NDA - Stock Titan
ALS patients whose nerve marker declined or stabilized lived longer, Clene says - Stock Titan
CLNN: Net loss widened to $13.4M in Q2 2026, with ongoing funding concerns and rising R&D costs - TradingView
Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CLNN Q2'26 Earnings: EPS estimate is (0.37) USD - TradingView
CLNN Q1 2026 Earnings: Narrower-than-Expected Loss of $0.27 per Share Lifts SharesEarnings Call Transcript - vinanet.vn
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS - MarketBeat
Clene Nanomedicine at canaccord growth conference: FDA path in focus By Investing.com - Investing.com Canada
Clene Inc. (CLNN) holder Ugwumba exits, reports 0% beneficial stake - Stock Titan
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Clene reports survival benefit in ALS patients with NfL response By Investing.com - Investing.com UK
Empery Asset Management, LP Buys Clene Inc (CLNN) -- Shares Look 486% Overvalued on GF Value - GuruFocus
Finanzdaten der Clene Inc-Aktie (CLNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Clene Inc-Aktie (CLNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):